Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics Licenses High-Content Screening Patents to GE Healthcare

NEW YORK, June 22 (GenomeWeb News) - Cellomics has non-exclusively licensed its high-content screening patents to GE Healthcare and has agreed to allow GE Healthcare to sublicense these patent rights to pharmaceutical companies, the company said today.

 

Financial details of the two agreements were not disclosed.

 

Cellomics, of Pittsburgh, Pa., said it has over 30 issued or allowed patents and an additional 30 patents pending in high content screening, an type of cellular assay it invented and defined.

 

GE Healthcare was created from the combination of GE Medical Systems and Amersham Biosciences, after Amersham's acquisition by GE.

 

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.